Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biospecifics Tech Cp (NQ: BSTC )

88.53 USD UNCHANGED
Last Price Updated: 4:21 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biospecifics Tech Cp

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
BioSpecifics Technologies Corp. Reports Third Quarter 2015 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
17 Biotechnology Stocks to Buy Now
 
Tags :SBBP NASDAQ:UTHR NASDAQ:SRPT
From InvestorPlace
BioSpecifics Technologies Corp. Announces Partner Endo International Exercises Early Opt-In for XIAFLEX for Two New Indications
- Company to receive opt-in fee of $0.5M for each new indication; lateral thigh fat and plantar fibromatosis - 
From PR Newswire
Biggest Movers in Manufacturing Stocks Now – GLDC ALG ORBK XXIA
 
Tags NYSE:CKP NASDAQ:ASTE NASDAQ:EGLT
From InvestorPlace
BioSpecifics Technologies Corp. to Report Third Quarter 2015 Financial Results on Monday, November 9, 2015
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
16 Biotechnology Stocks to Buy Now
 
Tags :APHB NASDAQ:BIOC NASDAQ:ISIS
From InvestorPlace
BioSpecifics Technologies Corp. Announces First Commercial Sale of XIAFLEX® for the Treatment of Dupuytren's Contracture in Japan
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase ... 
Tags BSTC Benzinga News
From Benzinga
BioSpecifics Technologies Corp. Announces First Commercial Sale of XIAFLEX® for the Treatment of Dupuytren's Contracture in Japan
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Mid-Day Market Update: Joy Global Drops On Earnings Miss; Methode Electronics Shares Spike Higher
Midway through trading Thursday, the Dow traded up 0.33 percent to 16,405.76 while the NASDAQ climbed 0.77 percent to 4,786.68. The ... 
Tags Commodities KERX Intraday Update
From Benzinga
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
BioSpecifics Technologies Corp. Announces Formal Pricing of XIAFLEX® for the Treatment of Dupuytren's Contracture in Japan
- Milestone payable upon commercial launch - 
From PR Newswire
Mid-Day Market Update: National Penn Bancshares Surges On Acquisition News; Vera Bradley Shares Slide
Midway through trading Tuesday, the Dow traded down 0.14 percent to 17,520.46 while the NASDAQ slipped 0.38 percent to 5,072.33. The ... 
Tags Benzinga Econ #s Movers
From Benzinga
BioSpecifics Technologies Corp. Announces Board Authorization of up to $2.5 Million Stock Repurchase Program
From PR Newswire
BioSpecifics Technologies Corp. Reports Second Quarter 2015 Financial Results
From PR Newswire
BioSpecifics Technologies Corp. to Report Second Quarter 2015 Financial Results on Monday, August 10, 2015
From PR Newswire
The First Half of 2015 Was a Huge Win for Biotech Investors: Here Are the Top Picks of the Top Stock Pickers for Q3 & Q4
Tags Business & Professional Services
From ACCESSWIRE
BioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, ... 
Tags BSTC Benzinga Press Releases
From Benzinga
BioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture
From PR Newswire
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
From PR Newswire
BioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference
From PR Newswire
BioSpecifics Reports Presentation of First Ever Treatment Guidelines for Peyronie's Disease and XIAFLEX Efficacy Data at AUA 2015 Annual Meeting
From PR Newswire
BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results
- Strong XIAFLEX sales drive robust Q1 2015 financial results - 
From PR Newswire
BioSpecifics Technologies Corp. to Present at the 2015 UBS Global Healthcare Conference
From PR Newswire
BioSpecifics Technologies Corp. to Report First Quarter 2015 Financial Results on Monday, May 11, 2015
From PR Newswire
BioSpecifics Announces Appointment of Jennifer Chao and Jyrki Mattila, M.D., Ph.D. to Board of Directors
From PR Newswire
BioSpecifics Technologies Corp. to Present at the 14th Annual Needham Healthcare Conference
From PR Newswire
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2014 Financial Results
From PR Newswire
BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015
From PR Newswire
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
From PR Newswire
BioSpecifics Technologies Corp. Announces Approval of XIAPEX® in the EU for the Treatment of Peyronie's Disease
From PR Newswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.